Embedded Files
DelveInsight's comprehensive "Non-Alcoholic Fatty Liver Disease Pipeline Analysis 2025" delivers extensive intelligence on over 90 organizations and more than 100 developmental drugs within the Non-Alcoholic Fatty Liver Disease sector. The analysis encompasses detailed profiles of Non-Alcoholic Fatty Liver Disease pipeline candidates across both clinical and preclinical phases. Coverage includes therapeutic evaluation by product classification, developmental phase, administration method, and molecular category. The report also spotlights dormant pipeline assets in this therapeutic area.
Explore the most recent drugs and treatment alternatives in the Non-Alcoholic Fatty Liver Disease Pipeline. Access DelveInsight's comprehensive analysis today! @ Non-Alcoholic Fatty Liver Disease Pipeline Outlook
Major Highlights from the Non-Alcoholic Fatty Liver Disease Pipeline Analysis
Major Highlights from the Non-Alcoholic Fatty Liver Disease Pipeline Analysis
On November 3, 2025, Boehringer Ingelheim launched a trial to determine whether a medication called survodutide assists individuals living with obesity or overweight and a confirmed or presumed liver condition called nonalcoholic steatohepatitis (NASH) to reduce liver fat and lose weight. Participants are allocated into 2 groups randomly, meaning by chance. 1 group receives different doses of survodutide and 1 group receives placebo. Placebo resembles survodutide but contains no active medication. Every participant has a 2 in 3 probability of receiving survodutide. Participants and physicians do not know who is in which group.
On October 31, 2025, GlaxoSmithKline revealed a trial to evaluate the safety profile and effectiveness of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcomes compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
On October 31, 2025, Novo Nordisk A/S commenced a trial that will span approximately 5 years. Participants will have up to 21 clinic appointments and 9 telephone consultations with the clinical staff throughout the study. Some of the clinic appointments may be distributed over more than one day. Participants with other chronic liver conditions cannot participate in this trial. Women cannot participate in the trial if they are pregnant, breast-feeding, or plan to become pregnant during the study duration.
On October 28, 2025, AstraZeneca initiated a trial to Evaluate the Efficacy, Safety, and Tolerability of AZD2693 administered by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele.
DelveInsight's Non-Alcoholic Fatty Liver Disease pipeline analysis illustrates a dynamic landscape with over 90 active organizations working to advance more than 100 pipeline treatments for Non-Alcoholic Fatty Liver Disease applications.
The prominent Non-Alcoholic Fatty Liver Disease Organizations include Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and additional entities.
Notable Non-Alcoholic Fatty Liver Disease Pipeline Treatments include Semaglutide, HEC96719, DA-1241, Sitagliptin, and additional candidates.
Stay ahead with the most current pipeline perspective for Non-Alcoholic Fatty Liver Disease. Gain intelligence into clinical trials, emerging treatments, and leading organizations with DelveInsight @ Non-Alcoholic Fatty Liver Disease Treatment Drugs
NAFLD Background
NAFLD Background
Non-alcoholic fatty liver disease (NAFLD) represents a broad term used to encompass a spectrum of conditions that are distinguished by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis including significant alcohol consumption, chronic use of medications that can cause hepatic steatosis, or hereditary disorders. The prevalence of NAFLD in western nations is approximately 20 to 30%. Obesity, diabetes, dyslipidemia, insulin resistance, and metabolic syndrome are recognized to be associated with the development of non-alcoholic fatty liver disease (NAFLD). A temporal association has also been demonstrated between inorganic arsenic exposure and the development of NAFLD reflected by elevated alanine transferase (ALT). Due to its close association with metabolic syndrome, NAFLD correlates with cardiovascular risk factors, which also contributes to mortality in these individuals in addition to end-stage liver cirrhosis and hepatocellular carcinoma.
Non-Alcoholic Fatty Liver Disease Emerging Drug Profiles
Non-Alcoholic Fatty Liver Disease Emerging Drug Profiles
Lanifibranor: Inventiva Pharma
Lanifibranor represents an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the organism by activating each of the three PPAR isoforms, designated as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ and partial activation of PPARɣ. Presently, the treatment is advancing through Phase II clinical trial for Non-Alcoholic Fatty Liver Disease.
ZED 1227: Dr. Falk Pharma GmbH
ZED 1227 represents a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European nations and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is anticipated to improve liver fibrosis in individuals with NAFLD. Presently, the treatment is advancing through Phase II clinical trial for Non-Alcoholic Fatty Liver Disease.
TVB-2640: Sagimet Biosciences
TVB-2640 represents an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation, and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II investigation for moderate to severe acne. Presently, the treatment is advancing through Phase II clinical trial for Non-Alcoholic Fatty Liver Disease.
ALS-L1023: AngioLab
ALS L1023 represents a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. Presently, the treatment is advancing through Phase II clinical trial for Non-Alcoholic Fatty Liver Disease.
AZD9550: AstraZeneca
AZD9550 represents a GLP-1R glucagon dual agonist small molecule which is in early development for the treatment of NASH (non-alcoholic steatohepatitis), a type of liver condition that commonly affects overweight and obese individuals who have T2DM. Presently, the treatment is advancing through Phase I/II clinical trials for Non-Alcoholic Fatty Liver Disease.
The Non-Alcoholic Fatty Liver Disease Pipeline Analysis Provides Intelligence Into
The Non-Alcoholic Fatty Liver Disease Pipeline Analysis Provides Intelligence Into
The analysis delivers detailed intelligence about organizations developing therapies for Non-Alcoholic Fatty Liver Disease treatment with aggregate therapies developed by each organization for the same.
It evaluates the various therapeutic candidates segmented into early-phase, mid-phase, and late-phase of development for Non-Alcoholic Fatty Liver Disease Treatment.
Non-Alcoholic Fatty Liver Disease Organizations are engaged in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Alcoholic Fatty Liver Disease Drugs under development categorized by the developmental phase, administration method, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classification.
Comprehensive analysis of partnerships (organization-organization partnerships and organization-academia partnerships), licensing agreements, and financing details for future progression of the Non-Alcoholic Fatty Liver Disease market.
Explore groundbreaking treatments and clinical trials in the Non-Alcoholic Fatty Liver Disease Pipeline. Access DelveInsight's detailed analysis now! @ New Non-Alcoholic Fatty Liver Disease Drugs
Non-Alcoholic Fatty Liver Disease Organizations
Non-Alcoholic Fatty Liver Disease Organizations
Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and additional entities.
Non-Alcoholic Fatty Liver Disease Pipeline Analysis Delivers Therapeutic Evaluation by Route of Administration
Non-Alcoholic Fatty Liver Disease Pipeline Analysis Delivers Therapeutic Evaluation by Route of Administration
Products have been classified under various ROAs including:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Non-Alcoholic Fatty Liver Disease Products Have Been Classified Under Various Molecular Types Including:
Non-Alcoholic Fatty Liver Disease Products Have Been Classified Under Various Molecular Types Including:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Non-Alcoholic Fatty Liver Disease Treatment. Learn about new drugs, pipeline developments, and key organizations with DelveInsight's expert analysis @ Non-Alcoholic Fatty Liver Disease Market Drivers and Barriers
Scope of the Non-Alcoholic Fatty Liver Disease Pipeline Analysis
Scope of the Non-Alcoholic Fatty Liver Disease Pipeline Analysis
Coverage: Global
Non-Alcoholic Fatty Liver Disease Organizations: Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel, Inventiva Pharma, Galectin Therapeutics, AngioLab, MediciNova, AstraZeneca and additional entities.
Non-Alcoholic Fatty Liver Disease Pipeline Treatments: Semaglutide, HEC96719, DA-1241, Sitagliptin, and additional candidates.
Non-Alcoholic Fatty Liver Disease Therapeutic Evaluation by Product Type: Mono, Combination, Mono/Combination
Non-Alcoholic Fatty Liver Disease Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Non-Alcoholic Fatty Liver Disease Treatments and clinical trials. Download DelveInsight's in-depth pipeline analysis today! @ Non-Alcoholic Fatty Liver Disease Companies, Key Products and Unmet Needs
Table of Contents
Table of Contents
Introduction
Executive Summary
Non-Alcoholic Fatty Liver Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lanifibranor: Inventiva Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ZED 1227: Dr. Falk Pharma GmbH
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AZD9550: AstraZeneca
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Non-Alcoholic Fatty Liver Disease Key Companies
Non-Alcoholic Fatty Liver Disease Key Products
Non-Alcoholic Fatty Liver Disease - Unmet Needs
Non-Alcoholic Fatty Liver Disease - Market Drivers and Barriers
Non-Alcoholic Fatty Liver Disease - Future Perspectives and Conclusion
Non-Alcoholic Fatty Liver Disease Analyst Views
Non-Alcoholic Fatty Liver Disease Key Companies
Appendix
About Us
About Us
DelveInsight is a premier healthcare-focused market research and consulting organization that delivers clients with superior market intelligence and analysis to support informed business decisions. With a team of seasoned industry specialists and a profound understanding of the life sciences and healthcare sectors, we offer tailored research solutions and intelligence to clients globally. Connect with us to obtain superior, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse